

Xiphophorus hybrid fish model. *Proc Natl Acad Sci USA* 107:9329–34

Mouret S, Baudouin C, Charveron M *et al.* (2006) Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. *Proc Natl Acad Sci USA* 103:13765–70

Pouget J-P, Douki T, Richard M-J *et al.* (2000) DNA

damage induced in cells by gamma and UVA radiation as measured by HPLC/GC-MS and HPLC-EC and comet assay. *Chem Res Toxicol* 13:541–9

Rizzo JL, Dunn J, Rees A *et al.* (2011) No formation of DNA double-strand breaks and no activation of recombination repair with UVA. *J Invest Dermatol* 131:1139–48

inflammatory disorder (Davidovici *et al.*, 2010; Menter *et al.*, 2008).

Two recent studies have added to this previously summarized literature. First, Ahlehoff *et al.* (2010), in a nationwide Danish study of 34,371 people with mild psoriasis and 2,621 with severe psoriasis, demonstrated independent risk ratios (RRs) for CV death of 1.14 (95% confidence interval (95% CI) 1.06–1.22) and 1.57 (95% CI 1.27–1.94), respectively, with the greatest increase in young people (ages 18–50, RR 2.98, 95% CI 1.32–6.73) with severe disease. The authors also compared CV risks in patients with severe psoriasis with the risks in patients with diabetes mellitus and found comparable increases in major adverse CV events and CV deaths in these groups, demonstrating the clinical importance of the risk of CV disease attributable to psoriasis. Other recent studies have investigated the clinical significance of CV risk in patients with severe psoriasis, demonstrating that these patients have about a 6-year reduction in life expectancy and that excess risk of CV death is the largest contributor to this premature mortality (Abuabara *et al.*, 2010).

#### PUVA follow-up study

In contrast to all of this prior work, Stern and Huibregtse (2011) report that the risk of CV death was not increased compared with that in the US population (standardized mortality ratio (SMR) 1.02, 95% CI 0.90–1.16) and that the risk of CV death was slightly but not statistically significantly higher in patients in the highest quartile of extent of psoriasis compared with those in the lowest quartile (hazard ratio (HR) adjusted for age and sex 1.37, 95% CI 0.97–1.94, multivariate HR 1.23, 95% CI 1.23, 95% CI 0.85–1.80). Additionally, the authors found no increase in frequency of obesity in their cohort of severe psoriasis patients compared with the general US population and no statistically significant association of obesity with CV mortality, despite vast bodies of literature establishing these strong associations (Azfar and Gelfand, 2008; Davidovici *et al.*, 2010; Flegal *et al.*, 2007; Love *et al.*, 2010; Menter *et al.*, 2008; Zhang *et al.*, 2008). Basic principles of epidemiological study design

See related article on pg 1159

## Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II

Joel M. Gelfand<sup>1,2,3</sup>, Nehal N. Mehta<sup>3,4</sup> and Sinéad M. Langan<sup>1,2,3</sup>

The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a “visible killer,” as four decades ago (after many years of controversy) hypertension was recognized to be a “silent killer.”

*Journal of Investigative Dermatology* (2011) 131, 1007–1010. doi:10.1038/jid.2011.32

#### What is known about psoriasis and cardiovascular risk?

As recently reviewed in this journal, the evolving evidence from the epidemiological literature suggests that patients with psoriasis severe enough to require systemic medications or phototherapy have an increased prevalence of major cardiovascular (CV) risk factors and a clinically significant increased risk of

major CV events such as myocardial infarction, stroke, and CV death that is independent of conventional risk factors (Gelfand *et al.*, 2010). These epidemiological studies, combined with a better understanding of the pathophysiology of psoriasis, have led to the recognition that psoriasis may have the potential to affect more than skin; it is now considered a systemic

<sup>1</sup>Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; <sup>2</sup>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; <sup>3</sup>The Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA and <sup>4</sup>Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

**Correspondence:** Joel M. Gelfand, Department of Dermatology, 1470 Penn Tower, 1 Convention Avenue, Philadelphia, Pennsylvania 19104, USA. E-mail: Joel.Gelfand@uphs.upenn.edu

**Table 1. Relevant definitions**

Bias	Any systematic error in the design, conduct, or analysis of a study that results in a mistaken estimate of an exposure's effect on the risk of disease
Selection bias	Any systematic error that arises from methods to select participants for inclusion in a study that is differentially related to the odds of developing the outcome of interest
Information bias	Any systematic error in measuring exposure or outcome resulting in differential accuracy of information between groups
Confounding	An observed association (or lack of one) caused by a mixing of effects among the exposure, the disease, and a third factor (a confounding variable). By definition, a confounding variable is associated with the exposure and, independent of that exposure, affects the risk of developing the disease
Statistical error, type I	The effect is interpreted as significant (i.e., an association exists) when in fact the association is caused by chance. Type I error is determined by the <i>P</i> value. The risk of type I error increases with multiple comparisons
Statistical error, type II	The effect is interpreted as not significant (i.e., there is no association), when in fact the association does exist. Type II error is estimated by statistical power. The actual power of the study is determined by the range of the 95% confidence interval
Confidence interval	This represents the range within which the true magnitude of the effect in a population lies with a certain degree of confidence. With a 95% confidence interval, this means that if the study were repeated 100 times, 95% of the observations would occur within the confidence interval

From Hennekens and Buring, 1987.

may help explain the discrepancy between the mortality experience in the Psoralen plus Ultraviolet-A (PUVA) follow-up study and studies of psoriasis patients identified using population-based methods.

### Principles of epidemiological study design relevant to reconciling the results

Epidemiologists attempt to design observational studies using methods that minimize bias (selection and information), confounding, and statistical error (Table 1 and Figure 1). To achieve these goals, modern approaches rely on "population-based" designs (Figure 1). Population-based studies are defined as those in which the cases (or exposed patients in cohort studies) are a representative sample of all cases (or exposed patients in cohort studies) in a well-defined population, and the controls are sampled directly from the same source population from which the cases (or exposed patients in cohort studies) were derived (Strom, 2005). Thus, an advantage of population-based studies is that the comparison group is from the same source population from which the exposed cohort was derived, a basic requirement for minimizing selection bias (Hennekens and Buring, 1987).

**Selection bias.** In contrast to the other studies described above, the PUVA follow-up study was not population based; subjects were derived from a clinical trial of a novel therapeutic intervention ( $n = 1,450$ ) conducted at 16 leading academic dermatology centers in the United States in 1975–1976 (Melski *et al.*, 1977). Further, and critically, the study did not have an internal comparison group. Instead, the authors compared the PUVA mortality experience with that of the general US white population, calculating an SMR. Comparing a study population that was willing and able to have its health status carefully monitored by the investigators for decades with the general US white population introduces selection bias because the study subjects differ from the general white US population in important ways that could affect mortality rates. Furthermore, it has been recognized for many years that patients who participate in clinical trials tend to be healthier than patients with the disease of interest who do not participate (Britton *et al.*, 1999; Rothwell, 2005). Thus, it is probable that the study compares apples to oranges. Based on factors inherent to selection and participation, patients in the PUVA cohort are more likely to have different

health-seeking behaviors, higher socioeconomic status, and access to higher-quality medical care compared with the general white US population, akin to the "healthy worker effect" in occupational cohort studies; therefore, direct comparison of these groups may be erroneous (Britton *et al.*, 1999). Moreover, even when these basic criteria are met (the best-case scenario), SMRs have been shown to underestimate mortality risk associated with exposures compared with using a more appropriate internal control group (Card *et al.*, 2006). Finally, detailed data necessary for interpreting mortality studies, such as prevalence of major risk factors for death (e.g., history of cancer, atherosclerosis, diabetes, and hyperlipidemia), are not reported.

An equally important problem with using general US rates is that they do not capture the huge variation in all-cause and CV mortality rates among states (and even within states) in the United States. For example, one of the study centers was from a state (Minnesota) that has the lowest CV mortality rate in the United States (27% lower than the national mean and 81% lower than the state with the highest CV mortality rate; Rosamond *et al.*, 2008).

As a result, one cannot determine whether the mortality experience of the PUVA cohort was attributable to the patients' being more health conscious, their having better access to medical care at academic medical centers, their having better socioeconomic status, etc., and/or the variations in mortality that exist among the states.

**Information bias: measurement of outcome.** In this study, mortality experience in psoriasis patients was determined on the basis of telephone interviews with patients, clinicians, or patients' relatives or extraction from death certificates and review by the authors if there was ambiguity (15% of cases). Death rates for the US population were derived from routine data sources. The different approaches used to ascertain the cause of death may introduce information bias (Table 1 and Figure 1). If this error is random, then typically bias toward the null would result. However, if the error is systematic, then the direction of bias could be difficult to determine. Importantly, the authors do not

describe any deaths related to accidents or Alzheimer's disease (the fifth and sixth most common causes of deaths in the United States; Xu, 2010). Based on routine statistics, about 31 deaths would have been expected from accidents and 19 deaths from Alzheimer's disease. The absence of these major causes of death in this study could be attributable to either the method of data extraction or the fact that this is a specialized population with mortality experience different from that of the general US population.

**Information bias: measurement of exposure.** Stern and Huibregtse (2011) attempt to address the fundamental limitations of their primary analysis (selection bias and the lack of an internal comparator) by examining the risk of mortality among patients with psoriasis of varying severity. Severity was assessed at one point in time and divided into quartiles based on the body surface area (BSA) involved. The lowest quartile included patients meeting the definition of moderate to severe psoriasis, and thus a comparison to an internal group of mild psoriasis patients was not conducted (Kurd and Gelfand, 2009). Psoriasis severity and exposure to the majority of covariates were based on assessment at the study outset three decades prior to study completion. Therefore, the findings represent associations between psoriasis extent at one point in time and mortality decades later. Changes

in covariates with time were considered for smoking, PUVA, and methotrexate dose; however, these were categorized as "more than the mean exposure" that year or not, rather than either as a binary "yes/no" variable or a time-varying covariate. Given the age distribution of the study population in 1976 (5–85 years), significant changes are also likely to have occurred in psoriasis severity as well as in the measured covariates (blood pressure, body mass index) and unmeasured covariates (e.g., lipids and glucose) (Nijsten *et al.*, 2007). Additionally, several of the exposures included as confounders in this analysis (e.g., uric acid level) are potentially in the causal pathway between psoriasis and CV disease; therefore, their inclusion in multivariable analyses could erroneously mask important associations (Feig *et al.*, 2008). Given these analytic issues, the observation of excess mortality based on a single measurement of affected BSA more than 30 years earlier among a cohort of patients with severe psoriasis is remarkable. To put this finding in perspective, being in the top quartile of psoriasis severity in the PUVA cohort was associated with mortality (HR 1.55, 95% CI 1.23–1.93) to a greater extent than being in the top 15th percentile for obesity (HR 1.27, 95% CI 1.03–1.57).

**Statistical error.** One of the study objectives was to compare mortality experience between groups of patients

with the most ( $n = 349$ ) and least ( $n = 326$ ) extensive psoriasis, bearing in mind that all participants had severe disease. The authors found an HR of 1.37 (95% CI 0.97–1.94) for CV mortality in the most severe group. The wide confidence interval demonstrates a lack of statistical power to detect a clinically meaningful higher CV mortality (type II error). For example, in their multivariable models the top quartile of psoriasis severity was associated with a similar degree of risk as well-established risk factors such as smoking (HR 1.35, 95% CI 1.03–1.77). Moreover, the estimate of CV mortality in the most severe group is statistically similar (based on 95% CI) to that observed in prior population-based studies assessing major CV events (Ahlehoff *et al.*, 2010; Brauchli *et al.*, 2009; Gelfand *et al.*, 2006, 2009; Kaye *et al.*, 2008; Mehta *et al.*, 2009; Xiao *et al.*, 2009).

#### What are the conclusions and future directions?

As indicated by Stern and Huibregtse (2011) and consensus statements from the editors of the *American Journal of Cardiology* and the Medical Board of the National Psoriasis Foundation, clinicians should screen patients with severe psoriasis for CV risk factors and be sure that patients with risk factors receive appropriate counseling and treatment (Friedewald *et al.*, 2008; Kimball *et al.*, 2008). The potential benefit of setting more aggressive cardioprotective treatment goals for patients with severe psoriasis, as has been recommended for patients with other inflammatory diseases having similar evidence of excess CV risk (e.g., rheumatoid arthritis), should be explored further (Peters *et al.*, 2010). To investigate these issues more fully, we have established a population-based cohort study of more than 4,000 patients with varying levels of psoriasis severity who are being followed prospectively for major CV events (Seminara *et al.*, 2010). Furthermore, based on the evolving understanding of the systemic nature of psoriasis, a critical goal is to move interventional trials in psoriasis beyond short-term assessments of changes in skin disease and quality of life, toward longer-term assessments




Figure 1. Unified concept of analytical epidemiology studies, highlighting the major sources of error.



of the impact of treatment on the risk of developing CV, metabolic, and joint disease (i.e., psoriatic arthritis). Interestingly, the PUVA cohort found a 26% reduction in CV mortality (HR 0.74, 96% CI 0.56–0.97) in those receiving more than the mean number of PUVA treatments, suggesting that more aggressive treatment of psoriasis might improve health outcomes. Ultimately, randomized interventional trials will be necessary to determine whether severe psoriasis is in fact a “visible killer,” as (after many years of controversy) randomized trials starting in the 1960s demonstrated hypertension to be a “silent killer” (Freis, 1990).

**CONFLICT OF INTEREST**

JMG has received grants from Amgen, Pfizer, Novartis, and Abbott and is a consultant for Amgen, Novartis, Pfizer, Abbott, Celgene, and Centocor; none of the other authors states any conflict of interest.

**ACKNOWLEDGMENTS**

This study was supported by an R01 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (RO1HL089744 to JMG). The funders played no role in the design, analysis, or interpretation of this research. SML is funded by fellowships from the British Association of Dermatologists and the National Psoriasis Foundation. NNM is a recipient of the American College of Cardiology Young Investigator Award in the Metabolic Syndrome and grant K23HL097151-01 and is a recipient of the National Psoriasis Foundation Young Investigator Award. The authors appreciate helpful comments from Brian L Strom regarding early drafts of this Commentary.

**REFERENCES**

Abuabara K, Azfar RS, Shin DB *et al.* (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *Br J Dermatol* 163:586–92

Ahlehoff O, Gislason GH, Charlott M *et al.* (2010) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. *J Intern Med*; e-pub ahead of print 29 November 2010

Azfar R, Gelfand J (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. *Curr Opin Rheumatol* 20:416–22

Brauchli YB, Jick SS, Miret M *et al.* (2009) Psoriasis

and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. *Br J Dermatol* 160:1048–56

Britton A, McKee M, Black N *et al.* (1999) Threats to applicability of randomised trials: exclusions and selective participation. *J Health Serv Res Policy* 4:112–21

Card TR, Solaymani-Dodaran M, Hubbard R *et al.* (2006) Is an internal comparison better than using national data when estimating mortality in longitudinal studies? *J Epidemiol Community Health* 60:819–21

Davidovici BB, Sattar N, Prinz JC *et al.* (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol* 130:1785–96

Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. *N Engl J Med* 359:1811–21

Flegal KM, Graubard BI, Williamson DF *et al.* (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. *JAMA* 298:2028–37

Freis ED (1990) Reminiscences of the Veterans Administration trial of the treatment of hypertension. *Hypertension* 16:472–5

Friedewald VE, Cather JC, Gelfand JM *et al.* (2008) A/C editor’s consensus: psoriasis and coronary artery disease. *Am J Cardiol* 102:1631–43

Gelfand J, Neimann A, Shin D *et al.* (2006) Risk of myocardial infarction in patients with psoriasis. *JAMA* 296:1735–41

Gelfand J, Dommasch E, Shin D *et al.* (2009) The risk of stroke in patients with psoriasis. *J Invest Dermatol* 129:2411–8

Gelfand JM, Azfar RS, Mehta NN (2010) Psoriasis and cardiovascular risk: strength in numbers. *J Invest Dermatol* 130:919–22

Hennekens CH, Buring JE (1987) *Epidemiology in Medicine*. Little, Brown: Boston, MA

Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. *Br J Dermatol* 159:895–902

Kimball AB, Gladman D, Gelfand JM *et al.* (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. *J Am Acad Dermatol* 58:1031–42

Kurd SK, Gelfand JM (2009) The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. *J Am Acad Dermatol* 60:218–24

Love TJ, Qureshi AA, Karlson EW *et al.* (2010) Prevalence of the metabolic syndrome in

psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. *Arch Dermatol*; e-pub ahead of print 20 December 2010

Mehta N, Azfar R, Shin D *et al.* (2009) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Eur Heart J* 31:1000–6

Melski JW, Tanenbaum L, Parrish JA *et al.* (1977) Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. *J Invest Dermatol* 68:328–35

Menter A, Gottlieb A, Feldman SR *et al.* (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol* 58:826–50

Nijsten T, Looman CW, Stern RS (2007) Clinical severity of psoriasis in last 20 years of PUVA study. *Arch Dermatol* 143:1113–21

Peters MJ, Symmons DP, McCarey D *et al.* (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis* 69:325–31

Rosamond W, Flegal K, Furie K *et al.* (2008) Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 117:e25–146

Rothwell PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?” *Lancet* 365:82–93

Seminara NM, Abuabara K, Shin DB *et al.* (2010) Validity of The Health Improvement Network (THIN) for the study of psoriasis. *Br J Dermatol*; 104:602–9

Stern RS, Huibregtse A (2011) Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. *J Invest Dermatol* 131:1159–66

Strom B (2005) *Pharmacoepidemiology*. Wiley: New York

Xiao J, Chen LH, Tu YT *et al.* (2009) Prevalence of myocardial infarction in patients with psoriasis in central China. *J Eur Acad Dermatol Venereol* 23:1311–5

Xu JQ, Kochanek KD, Murphy SL *et al.* (2010) Deaths: final data for 2007. *Statistics* 58:1–135

Zhang C, Rexrode KM, van Dam RM *et al.* (2008) Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. *Circulation* 117:1658–67